LAVAL, QC / ACCESSWIRE / March 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced that members of company management will participate at the Cowen Annual Health Care Conference in Boston on March 5, 2024. The Bausch Health team will be hosting a fireside chat at 12:50 p.m. EST, and a live webcast will be accessible through the Investor Relations section of the Bausch Health website at https://ir.bauschhealth.com/. A replay of the webcast will be posted after the presentation and will be available for a limited time following the event.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.
Investor Contact:
Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
(877) 281-6642 (toll free)
Media Contact:
Kevin Wiggins
This email address is being protected from spambots. You need JavaScript enabled to view it.
(908) 541-3785
Last Trade: | US$7.33 |
Daily Change: | -0.02 -0.27 |
Daily Volume: | 735,187 |
Market Cap: | US$2.710B |
July 30, 2025 July 29, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load